Coagulation and Bleeding Disorders

 Bleeding is one of the most primal responses of the human body to injury. In most cases, it stops on its own within minutes, thanks to a tightly controlled biological process called haemostasis. But when haemostasis fails — whether because a vessel bleeds too much, too long, or clots too easily — the consequences can range from uncomfortable bruising to life-threatening haemorrhage.

The medical laboratory is at the heart of diagnosing and monitoring bleeding and clotting disorders. Through a carefully selected panel of tests, clinical scientists can pinpoint exactly where the haemostatic system has broken down and guide clinicians toward the right treatment. In this post, we take a deep dive into the science of coagulation, the most common disorders associated with it, and the laboratory tests that help us understand them.

1. Haemostasis: The Body's Clotting System

Haemostasis is the process by which bleeding stops after injury. It involves three overlapping phases that work together in seconds to minutes: primary haemostasis, secondary haemostasis, and fibrinolysis.

1.1 Primary Haemostasis

The moment a blood vessel is injured, collagen beneath the endothelium is exposed. Von Willebrand factor (vWF), a large multimeric glycoprotein, acts as a bridge between the exposed collagen and platelet surface receptors (specifically GPIb). This binding causes platelets to adhere to the damaged site.

Once adhered, platelets become activated. They change shape, release granule contents (ADP, thromboxane A2, serotonin), and recruit more platelets to the site. These platelets then bind to each other through fibrinogen bridges at GPIIb/IIIa receptors, forming the primary platelet plug — a temporary seal over the wound.

1.2 Secondary Haemostasis (Coagulation Cascade)

The platelet plug is fragile. Secondary haemostasis reinforces it with fibrin, the product of the coagulation cascade. The cascade involves a series of clotting factors (mostly serine proteases circulating in inactive forms called zymogens) that are activated sequentially.

The cascade has two pathways:

• Extrinsic pathway (Tissue Factor pathway): Triggered when tissue factor (TF), exposed at the site of injury, binds with Factor VIIa. This complex activates Factor X.

• Intrinsic pathway (Contact activation pathway): Triggered when Factor XII comes into contact with negatively charged surfaces (like collagen). This eventually activates Factor X through a series of steps involving Factors XII, XI, IX, and VIII.

Both pathways converge at the common pathway: Factor Xa combines with Factor Va to form the prothrombinase complex, which converts prothrombin (Factor II) into thrombin. Thrombin then cleaves fibrinogen into fibrin monomers, which polymerise and are cross-linked by Factor XIIIa to form a stable clot.

1.3 Fibrinolysis

Once the vessel wall is repaired, the clot must be dissolved. Tissue plasminogen activator (tPA) converts plasminogen to plasmin, which degrades fibrin into fibrin degradation products (FDPs), including D-dimer. This process is regulated by inhibitors such as alpha-2-antiplasmin and TAFI (thrombin-activatable fibrinolysis inhibitor).

2. Common Bleeding Disorders

2.1 Haemophilia A and B

Haemophilia is an X-linked recessive disorder characterised by deficiency of a clotting factor. Haemophilia A involves Factor VIII deficiency, while Haemophilia B involves Factor IX deficiency. Both result in impaired secondary haemostasis and present with deep muscle bleeds, haemarthroses (bleeding into joints), and prolonged bleeding after surgery or trauma.

Laboratory findings in haemophilia include a prolonged aPTT with a normal PT and normal bleeding time (since platelets function normally). Specific factor assays confirm the diagnosis and severity:

• Severe: <1% factor activity

• Moderate: 1–5% factor activity

• Mild: 5–40% factor activity

2.2 Von Willebrand Disease (vWD)

vWD is the most common inherited bleeding disorder, caused by quantitative or qualitative deficiency of vWF. Since vWF also serves as a carrier for Factor VIII, patients with severe vWD may also have low Factor VIII levels. vWD presents with mucocutaneous bleeding — nosebleeds, heavy menstrual periods, and easy bruising.

Laboratory testing includes: Bleeding time or PFA-100 (prolonged), vWF antigen level, vWF ristocetin cofactor activity, and Factor VIII level. Multimer analysis is used to classify the subtype.

2.3 Immune Thrombocytopenic Purpura (ITP)

ITP is an autoimmune condition in which antibodies target platelet surface antigens (commonly GPIIb/IIIa), leading to platelet destruction. It presents with petechiae, purpura, and mucocutaneous bleeding. CBC shows isolated thrombocytopenia. The blood film shows large, immature platelets. The diagnosis is largely clinical after exclusion of other causes.

2.4 Disseminated Intravascular Coagulation (DIC)

DIC is a severe, acquired disorder where widespread activation of coagulation leads to consumption of clotting factors and platelets, paradoxically causing both clotting and bleeding simultaneously. It is triggered by sepsis, trauma, obstetric complications, and malignancies.

Laboratory findings in DIC:

• Prolonged PT and aPTT

• Low fibrinogen

• Elevated D-dimer and FDPs

• Thrombocytopenia

• Low clotting factors (V, VIII)

• Fragmented red cells (schistocytes) on the blood film

2.5 Liver Disease and Coagulopathy

The liver synthesises almost all clotting factors (except vWF). In liver disease, reduced synthesis leads to coagulopathy. PT is typically the most sensitive early marker. Factor V levels are particularly useful because Factor V is not vitamin K-dependent, unlike Factors II, VII, IX, and X. Low Factor V in the context of liver disease suggests true hepatic synthetic failure rather than vitamin K deficiency.

3. The Laboratory Tests

3.1 Prothrombin Time (PT) and INR

The PT evaluates the extrinsic and common pathways (Factors I, II, V, VII, X). It is reported as INR (International Normalised Ratio) when used to monitor warfarin therapy. The INR corrects for differences in thromboplastin reagent sensitivity between laboratories.

3.2 Activated Partial Thromboplastin Time (aPTT)

The aPTT evaluates the intrinsic and common pathways (Factors I, II, V, VIII, IX, X, XI, XII). It is used to monitor unfractionated heparin therapy and to screen for haemophilia and lupus anticoagulant.

3.3 Fibrinogen

Fibrinogen (Factor I) is measured by the Clauss method (clotting method) and is critical in assessing DIC, liver disease, and thrombolytic therapy. Low fibrinogen (<1.5 g/L) in the context of DIC carries a poor prognosis.

3.4 D-Dimer

D-dimer is a fibrin degradation product formed when cross-linked fibrin is broken down by plasmin. It is highly sensitive but not specific for thrombosis. A negative D-dimer has high negative predictive value for DVT and pulmonary embolism. Elevated D-dimer also occurs in pregnancy, infection, malignancy, and post-surgery.

3.5 Thrombin Time (TT)

The TT measures the final step of coagulation — the conversion of fibrinogen to fibrin by thrombin. It is prolonged by heparin contamination (very sensitive), dysfibrinogenaemia, and very low fibrinogen levels.

3.6 Mixing Studies

When a prolonged PT or aPTT is found, a mixing study helps distinguish between factor deficiency and inhibitor presence. Patient plasma is mixed 1:1 with normal pooled plasma. Correction of the clotting time indicates factor deficiency; non-correction suggests an inhibitor (e.g., lupus anticoagulant, Factor VIII inhibitor).

4. Anticoagulant Monitoring in the Lab

Anticoagulant drugs require careful laboratory monitoring to ensure therapeutic levels are achieved without causing bleeding.

• Warfarin: Monitored by PT/INR. Target INR is usually 2.0–3.0 for most indications.

• Unfractionated heparin (UFH): Monitored by aPTT (target: 1.5–2.5 times the normal range) or anti-Xa level.

• Low molecular weight heparin (LMWH): Monitored by anti-Xa levels. Usually not required for standard doses in normal weight patients.

• Direct oral anticoagulants (DOACs): Routine monitoring not required, but anti-Xa (for rivaroxaban/apixaban) or dilute thrombin time (for dabigatran) can quantify drug levels when needed.

5. Key Clinical Tips for Laboratory Scientists

• Pre-analytical errors (improper tube fill, clotted samples, haemolysis) are the most common cause of spurious coagulation results.

• Coagulation samples must be collected in sodium citrate (blue-top) tubes and centrifuged promptly to produce platelet-poor plasma.

• Haematocrit above 55% requires adjustment of the citrate volume in the tube to avoid falsely prolonged results.

• Lupus anticoagulant (LA) can prolong aPTT but paradoxically causes thrombosis, not bleeding — always correlate with clinical findings.

• Factor VIII is an acute phase reactant — it can be elevated in inflammation, masking mild haemophilia A or vWD.

Conclusion

The haemostatic system is a marvel of biological engineering — precisely calibrated to respond to injury without going too far. When it fails, the laboratory becomes the first line of investigation. By understanding the cascade, the disorders that disrupt it, and the tests that reveal those disruptions, medical laboratory scientists play an indispensable role in patient care. Whether you are screening for bleeding risk before surgery or monitoring a patient on anticoagulation, the coagulation laboratory is where the answers are found.